Market Research Logo

Pancreatitis - Pipeline Review, H2 2018

Pancreatitis - Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pancreatitis - Pipeline Review, H2 2018, provides an overview of the Pancreatitis (Gastrointest


Global Markets Direct Report Coverage
Pancreatitis - Overview
Pancreatitis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Pancreatitis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Pancreatitis - Companies Involved in Therapeutics Development
Angion Biomedica Corp
Bharat Serums and Vaccines Ltd
CalciMedica Inc
Cypralis Ltd
DiaMedica Therapeutics Inc
Generon (Shanghai) Corp Ltd
GlaxoSmithKline Plc
LipimetiX Development Inc
MallInckrodt Plc
Novartis AG
Pharming Group NV
Shenzhen HighTide Biopharmaceutical Ltd
Sun BioPharma Inc
Takeda Pharmaceutical Co Ltd
Pancreatitis - Drug Profiles
AAD-2004 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AEM-2814 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ANG-3070 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
C1 esterase inhibitor (recombinant) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CBT-1430E - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CBT-1440G - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CC-1233 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CM-128 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CM-4620 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DM-300 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
F-652 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GSK-180 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GSK-2795039 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GSK-428 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GSK-6288B - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HTD-4010 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MP-3964 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NI-03 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PNB-028 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Peptides to Agonize renalase for Acute Pancreatitis, Acute Kidney Injury and Cisplatin Induced Kidney Injury - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein to Inhibit CXCL for Pancreatitis, Cardiovascular and Immunology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SBP-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SBP-102 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Block TRPV4 and TRPA1 for Pancreatitis and Trigeminal Neuralgia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Cyclophilin for Gastrointestinal and Musculoskeletal Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit KMO for Pancreatitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Soluble Epoxide Hydrolase for Acute Pancreatitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Trypsin for Pancreatitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SNB-201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TAK-671 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ulinastatin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Withaferin A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Pancreatitis - Dormant Projects
Pancreatitis - Discontinued Products
Pancreatitis - Product Development Milestones
Featured News & Press Releases
Aug 13, 2018: Samsung Bioepis to begin Phase l trial of SB26 for pancreatitis
May 01, 2018: CalciMedica Names Two Senior Executives to its Board of Directors
Nov 09, 2017: Cypralis to present pre-clinical data on novel cyclophilin D inhibitor CC-1233 for acute pancreatitis at the American Pancreatic Association meeting
Sep 18, 2017: Cypralis granted new Innovate UK feasibility stage award to develop cyclophilin inhibitors targeting fibrotic diseases
Aug 10, 2017: Sun BioPharma Provides Clinical Update
May 24, 2017: CalciMedica Receives Fast-Track Designation for CM4620, a Novel CRAC Channel Inhibitor to Treat Acute Pancreatitis
Feb 01, 2017: The NIH Awards Sun BioPharma Grant to Study SBP-101 for the Treatment of Pancreatitis
Jan 05, 2017: CalciMedica Initiates Phase 1 Clinical Studies for CRAC Channel Inhibitor
Oct 24, 2016: Sun BioPharma to Present at the Innovation Biotech Showcase on October 26th
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Pancreatitis, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Companies, H2 2018 (Contd..1), H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd..1), H2 2018
Products under Development by Universities/Institutes, H2 2018
Number of Products by Stage and Target, H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pancreatitis - Pipeline by Angion Biomedica Corp, H2 2018
Pancreatitis - Pipeline by Bharat Serums And Vaccines Ltd, H2 2018
Pancreatitis - Pipeline by CalciMedica Inc, H2 2018
Pancreatitis - Pipeline by Cypralis Ltd, H2 2018
Pancreatitis - Pipeline by DiaMedica Therapeutics Inc, H2 2018
Pancreatitis - Pipeline by Generon (Shanghai) Corp Ltd, H2 2018
Pancreatitis - Pipeline by GlaxoSmithKline Plc, H2 2018
Pancreatitis - Pipeline by LipimetiX Development Inc, H2 2018
Pancreatitis - Pipeline by MallInckrodt Plc, H2 2018
Pancreatitis - Pipeline by Novartis AG, H2 2018
Pancreatitis - Pipeline by Pharming Group NV, H2 2018
Pancreatitis - Pipeline by Shenzhen HighTide Biopharmaceutical Ltd, H2 2018
Pancreatitis - Pipeline by Sun BioPharma Inc, H2 2018
Pancreatitis - Pipeline by Takeda Pharmaceutical Co Ltd, H2 2018
Pancreatitis - Dormant Projects, H2 2018
Pancreatitis - Discontinued Products, H2 2018
List of Figures
Number of Products under Development for Pancreatitis, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Number of Products by Top 10 Targets, H2 2018
Number of Products by Stage and Top 10 Targets, H2 2018
Number of Products by Top 10 Mechanism of Actions, H2 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report